Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening endoscopy with a platelet count >150 3 10 9 cells/L and a liver stiffness measurement (LSM) <20 kPa (Baveno VI criteria). However, the total number of avoided endoscopies using this rule is relatively low. We aimed at expanding the Baveno VI criteria and validating them in additional cohorts. Patients from the Anticipate cohort (499 patients with cACLD of different etiologies) were used to study the performance of different thresholds of platelets and LSM for the identification of patients at very low risk (<5%) of having varices needing treatment (VNT). The new criteria (Expanded-Baveno VI) were validated in two additional cohorts from London (309 patients) and Barcelona (117 patients). The performance of the new criteria by etiology of cACLD was also assessed. The best new expanded classification rule was platelet count >110 3 10 9 cells/L and LSM <25 kPa. This was validated in the two additional cohorts. Overall, the Expanded-Baveno VI criteria would potentially spare 367 (40%) endoscopies (21% with Baveno VI criteria) with a risk of missing VNT of 1.6% (95% confidence interval, 0.7%-3.5%) in patients within the criteria and 0.6% (95% confidence interval, 0.3%-1.4%) in the overall population of 925 patients evaluated. The Expanded-Baveno VI criteria performed well in patients with cACLD with hepatitis C virus and alcoholic and nonalcoholic steatohepatitis. Conclusion: The new Expanded-Baveno VI criteria spare more endoscopies than the original criteria with a minimal risk of missing VNT in most of the main etiologies of cACLD. (HEPATOLOGY 2017;66:1980-1988.
cACLD identified in their early phases, the prevalence of varices and especially varices needing treatment (VNT; defined as per current Baveno VI guidelines as medium-large varices or small with red signs) is very low.
Based on preliminary information from studies suggesting that liver stiffness measurement (LSM) by transient elastography, in combination with other noninvasive parameters, was useful for "ruling out" patients with cACLD needing screening endoscopy, (4) (5) (6) (7) the Baveno VI recommendations indicated that patients with cACLD, an LSM <20 kPa, and a platelet count >150 3 10 9 cells/L have a very low risk of VNT and consequently can safely avoid the screening endoscopy. (1) Following that recommendation, several studies have now confirmed the validity of this risk classification rule, (8) (9) (10) (11) which allows sparing between 10% to 30% of screening endoscopies with a very low risk of missing VNT. However, due to the low prevalence of VNT in these patients with cACLD (<10%), up to 40% of unneeded endoscopies would still be performed. (10) Possible improvements to the current classification rule have been suggested. One regards the use of noninvasive tests (including platelets and LSM) for a continuous risk prediction model to individualize the decision to perform endoscopy (Anticipate study). (12) Other studies attempt to increase the number of spared endoscopies without increasing the risk of VNT missed. Jangouk et al. (13) reported a 12% increase in spared endoscopies (with no additional VNT missed) by expanding the Baveno VI criteria to patients with Model for End-Stage Liver Disease (MELD) 5 6. In addition, a stepwise strategy using platelet count >150 3 10 9 cells/L and MELD 5 6 without LSM, substantially increased the number of endoscopies avoided, maintaining a very low rate of missing VNT. Finally, changes in the platelet count and LSM cutoffs have also been suggested. (5) (6) (7) 14) The main aim of the present study was to find and validate a new classification rule for avoiding screening endoscopies in patients with cACLD to maximize the number of spared endoscopies while maintaining a very low risk of missing VNT (<5%). Secondary aims of our study were: 1) to analyze the performance of the new classification rule in different etiologies of cACLD and 2) to externally validate the Baveno VI/ MELD 5 6 and platelet/MELD 5 6 criteria and the performance of the ANTICIPATE continuous model.
Patients and Methods

STUDY COHORTS
Data from three different cohorts were retrospectively reviewed and analyzed (Table 1 ). In the Anticipate cohort, (12) from the European centers were reported, in part, in previous publications; however, there are no data regarding the total number of patients evaluated before the inclusion. (5, (15) (16) (17) Patients included in that study had cACLD of any etiology defined by LSM 10 kPa, Child-Pugh class A, and no prior liver decompensation. Patients who had paired data on noninvasive tests (blood tests and transient elastography) and endoscopy within 3 months were included. In total, 499 patients with LSM, endoscopy, and platelet count were available for the study.
The cohort from London (8) was selected from two institutions (Royal Free Hospital and St. Mary's Hospital), and a flow chart of patient inclusion has been reported. In summary, a total of 12,331 LSM performed between 2006 and 2015 were evaluated. Of them, 9,018 were excluded because of LSM <10 kPa, 548 due to inadequate LSM, 403 were repetitions, 81 had prior decompensation or splanchnic thrombosis, and 1,471 had no endoscopy within 12 months of elastography. Finally, 310 patients with cACLD were included in this cohort (Table 1) . One patient from this cohort had had a prior splenectomy and therefore had an unusually high platelet count; this patient was not considered for the validation as Baveno VI criteria could not be applied.
The third cohort, from Hospital Vall d'Hebron in Barcelona, was composed of 117 patients with cACLD with hepatitis C chronic infection evaluated before the initiation of direct-acting antivirals therapy in 2015. These patients were assessed with blood tests, transient elastography, and endoscopy between 2014 and 2015, and they do not overlap with the patients from Vall d'Hebron in the Anticipate study. Inclusion criteria were also LSM 10 kPa, Child-Pugh class A, no prior decompensation of liver disease, and endoscopy within 12 months of elastography. During this period, a total of 608 patients with hepatitis C virus (HCV) were evaluated for treatment. Unrealiable LSM was observed in 47 patients (7.7%), and 300 patients were patients with cACLD, from which 117 had an endoscopy performed within 12 months of elastography.
None of the patients with chronic hepatitis C were on antiviral treatment (interferon-based therapy or direct antivirals agents) at the time of inclusion or had previously received it.
TRANSIENT ELASTOGRAPHY
The three cohorts used transient elastography by Fibroscan (Echosens, Paris, France) to obtain an LSM. The quality criteria used in each cohort for LSM were the criteria recommended at the time of the inclusion of the cohorts: 10 valid measurements obtained with a success rate 60% and the interquartile range to median ratio 30%. An M probe was used in all measurements. Data of the number of unreliable/no valid LSM excluded are not available from the Anticipate cohort.
DESIGN OF THE STUDY
A sequential analysis plan was designed in order to provide responses for the different aims of the study. The different steps were the following: 1) the Anticipate cohort was first used to validate the performance of the Baveno VI criteria (1) ; 2) the same cohort was 69 (14) 14 (4.5) 9 (7.7) 92 (9.9)
Continuous data expressed as mean 6 SD. *BMI from the London cohort was not available. Abbreviations: ALT, alanine aminotransferase; BMI, body mass index.
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used to explore the expansion of criteria by adding the MELD 5 6 rule and the platelet/MELD 5 6 rule (13) ; 3) the Anticipate cohort was also used to study the expansion of Baveno criteria by using previously proposed modified LSM and platelet cutoffs (4) (5) (6) (7) 14) and selecting the best classification rule in terms of endoscopies spared while keeping the risk of missing VNT below 5%; 4) the new selected set of criteria (Expanded-Baveno VI) were then validated in the London and Vall d'Hebron cohorts; 5) the performance of the Anticipate continuous model for predicting risk of VNT was evaluated in the three cohorts by analyzing the rate of endoscopies saved with a decision risk threshold for VNT of 5%; 6) next, the MELD 5 6 criteria were again added to the new ExpandedBaveno VI criteria; 7) an analysis of the performance of the new criteria by etiology was subsequently carried out; 8) the effect of the variability of platelet count and LSM in the performance of the new criteria was finally evaluated.
STATISTICAL ANALYSIS
Continuous variables were reported as mean 6 SD. Qualitative variables were compared using the chisquare test. The main outcome of interest for the validation of criteria was the prevalence of VNT. VNT was defined according to Baveno VI recommendations as small varices (grade 1) with red signs in which betablocker therapy is indicated or large varices (grade 2 or 3) in which treatment with beta blockers or band ligation is needed to prevent first variceal bleeding.
(1) The main variable used for the optimization of criteria was the percentage of endoscopies spared while keeping the risk of missed VNT below the predefined arbitrary <5% threshold. This threshold was decided by experts in the Baveno VI consensus conference who agreed that 5% was a reasonable threshold for missing VNT; it was later endorsed by the American Gastroenterological Association technical review on hepatic elastography accepting a 5% false negative rate of missing high risk varices. (4, 12, 18) The choice of new cut-off values for the different parameters explored was based on published reports. (4) (5) (6) (7) 14) The development of the continuous risk prediction model for VNT by using LSM and platelets and its corresponding nomogram was extensively reported in the Anticipate study. (12) In brief, a continuous prediction model for VNT was developed by logistic regression using platelet count (capped at 150 3 10 9 cells/L) and LSM as covariates. The model was internally validated and corrected for optimism with bootstrapping. A nomogram for individual risk estimation was built based on the corrected logistic regression model. Data were processed using SPSS. For analyses, both SPSS and R statistical platforms were used.
Results
BAVENO VI CRITERIA IN THE ANTICIPATE COHORT
In the Anticipate cohort, 68 of 499 (14%) patients evaluated were within the Baveno VI criteria for not performing endoscopy (LSM <20 kPa and platelet count >150 3 10 9 cells/L) ( Table 2) . Among these 68 patients, 62 had no varices, 4 (6%) had low-risk varices, and 2 (3%; 95% confidence interval [CI], 0.8%-10%) presented VNT. This represents that only 2 of 499 patients (0.4%; 95% CI, 0.1%-1.4%) had VNT missed and were therefore misclassified. This result shows that Baveno VI criteria perform well in the (4, 5) 88 (17.5%) 3/88 (3.4%, 1.1%-9.5%) Platelets >150 1 LSM <30 kPa (14) 116 (23%) 6/116 (5%, 2.3%-10.8%) Platelets >125 1 LSM <25 kPa (14) 126 (25%) 3/126 (2.4%, 0.8%-6.7%) Platelets >120 1 LSM <25 kPa (7) 139 (28%) 3/139 (2.2%, 0.7%-6%)
158 (32%) 3/158 (1.9%, 0.6%-5.4%)
Platelets >100 1 LSM <25 kPa (4, 6) 182 (36.5%) 9/182 (5%, 2.6%-9%)
The bold line indicates the classification rule that was selected for subsequent analysis for being the one that spared more endoscopies without increasing the rate of VNT missed. *Reference number. † 95% CI.
Anticipate cohort, but the number of spared endoscopies was low.
BAVENO VI/MELD 5 6 AND PLATELET/MELD 5 6 RULES
In the Anticipate cohort, 463 patients had data to calculate the MELD score. Among these patients, 63/ 463 (13.6%) met the Baveno VI criteria for avoiding endoscopy with only 2/63 (3.1%; 95% CI, 0.9%-11%) VNT missed. Adding the MELD 5 6 criteria in those patients who did not meet the Baveno VI criteria, the number of spared endoscopies increased by 34/400 (8.5%) with no additional VNT missed. Thus, by adding the MELD 5 6 criteria to the Baveno VI criteria, a total of 97/463 (21%) endoscopies could be safely avoided with a low risk of missing VNT (2/97, 2%; 95% CI, 0.5%-7%), confirming that the number of spared endoscopies could be safely increased with a gain of 7% of endoscopies.
The other classification rule proposed by Jangouk et al. (13) was platelet count >150 3 10 9 cells/L or MELD 5 6 (without the use of LSM). In the Anticipate cohort, 161/463 (35%) patients had a platelet count >150 3 10 9 cells/L, of whom 13 patients (8%) had VNT. Twenty-three patients (5%) had a platelet count 150 3 10 9 cells/L and MELD 5 6 with no patients having VNT. Overall, the number of spared endoscopies with these criteria was 184 (39.7%) with 13/184 (7%; 95% CI, 4%-11.7%) VNT missed, indicating that more endoscopies might be saved but an excessive number of VNT (above the predefined objective of 5%) would be undetected.
EXPANDING THE BAVENO VI CRITERIA: THE EXPANDED-BAVENO VI CRITERIA
The exploratory data and the performance of new criteria based on the expansion of Baveno VI criteria by increasing the LSM cutoff and/or decreasing platelet count in the Anticipate cohort patients are shown in Table 2 . The combined use of platelet count >110 3 10 9 cells/L and LSM <25 kPa maximized the number of potentially spared endoscopies while keeping the rate of VNT missed below the predefined 5% threshold. We propose the name Expanded-Baveno VI criteria for this new classification rule.
VALIDATING THE EXPANDED-
The performance of the new criteria in all three cohorts is shown in Table 3 . Overall, the risk of missing VNT is very low (<2% with a maximum of 3.5% at the upper limit of the 95% CI), and on average, 40% of endoscopies are saved. The clinical characteristics of the 6 missed patients with VNT are described in Supporting Table S1 .
The risk distribution of VNT missed in the patients within the Baveno VI criteria and the additional patients detected by the new Expanded-Baveno VI criteria (in patients beyond the original Baveno VI criteria) are depicted in Table 4 . Remarkably, the risk of missing VNT is the same in both subgroups, suggesting that the new patients selected by the expanded criteria are not increasing the risk of missing VNT.
PERFORMANCE OF THE ANTICIPATE CONTINUOUS MODEL
By using the continuous predictive model of the Anticipate study with a decision threshold of 5% risk for VNT in the three cohorts (Table 5) , an almost identical observed risk of missing VNT was detected with the three classification methods. While the number of saved endoscopies was higher using the Anticipate continuous model than with the original Baveno VI criteria, the Expanded-Baveno VI criteria maximized the number of saved endoscopies.
ADDING THE MELD 5 6 TO THE EXPANDED-BAVENO VI CRITERIA
Overall, 883 patients from the three cohorts had information to calculate the MELD score and 357 (40.4%) were within the new Expanded-Baveno VI criteria. We tested the possibility of applying the MELD 5 6 criterion to identify patients at low risk among those not fulfilling the Expanded-Baveno VI criteria (n 5 526). The addition of patients identified with MELD 5 6 (48/526; 9%) to the 357 patients within the Expanded-Baveno VI criteria spared a total of 405 (45.8%) endoscopies, while the risk of missing VNT remained very low (1.7%; 95% CI, 0.8%-3.5%); the gain in endoscopies saved compared to the new criteria (40.4%) was 5.4% (Table 6 ).
PERFORMANCE OF THE EXPANDED-BAVENO VI CRITERIA BY ETIOLOGIES
A subgroup analysis by etiologies of cACLD in all patients from the three cohorts (Table 7) was performed. The main etiology was HCV, followed by alcoholic liver disease and nonalcoholic fatty liver disease. The new rule seems to perform very well in these three main etiologies. The risk of VNT ranged between 0% and 2.2%, and the number of spared endoscopies ranged between 38.5% and 49%. For other etiologies (hepatitis B, cholestatic diseases, mixed viral and alcohol), subgroup numbers were too low to reach robust conclusions.
EFFECT OF THE VARIABILITY OF THE PARAMETERS IN THE EXPANDED-BAVENO VI CRITERIA
The variability in LSM and platelet count determinations might have an impact in the proposed new criteria, mainly when dealing with values closer to the proposed cutoffs. Thus, a sensitivity analysis was conducted to account for the effects of the variability of measurements near those thresholds. Evidence from the literature indicates that with experienced personnel, LSM variability can reach 20%. (19) As for platelet counts, we performed a small evaluation in 15 patients with HCV, analyzing and comparing basal counts with 6-and 12-month prior determinations. Considering the extreme values, the oscillation was between -11% and 12%.
Therefore, taking into account the worst case scenario, that is 20% increase in LSM and 10% decrease in platelet count to the Expanded-Baveno VI criteria (platelet count >100 3 10 9 cells/L 1 LSM <30 kPa), 11 VNT would be missed in 127 additional patients (11/127, 8.6%-95%; CI, 5%-15%) not receiving endoscopy.
Discussion
In the present cooperative study, we provide evidence that the original Baveno VI criteria for the screening of varices in patients with cACLD can be safely expanded (Expanded-Baveno VI criteria), increasing the number of endoscopies that can be avoided to almost 50% while keeping the risk of missing VNT very low. In addition, we confirm the validity of the MELD 5 6 criteria added to the Baveno VI or Expanded-Baveno VI criteria, although the number of additionally saved endoscopies is low. Finally, the new classification rule seems to be applicable to all main etiologies of cACLD.
The Baveno VI consensus conference introduced some important novelties regarding the management of patients with cACLD/compensated cirrhosis, partly as a consequence of the increasing acceptance of noninvasive testing in chronic liver disease, especially transient elastography. The concept of cACLD, the criteria for avoiding screening endoscopy, and the criteria for selecting patients with clinically significant portal hypertension are all based on simple analytical and LSM values.
(1) The original Baveno VI criteria for the triage of patients for screening endoscopy for varices (platelet count >150 3 10 9 cells/L 1 LSM <20 kPa), although well validated in subsequent studies, (8) (9) (10) (11) were also perceived as conservative; the number of spared endoscopies was relatively low, and about 40% of unneeded endoscopies would be performed using those criteria. (10) With the new Expanded-Baveno VI criteria (platelet count >110 3 10 9 cells/L 1 LSM <25 kPa), the number of spared endoscopies could be doubled (from 21% to 40%) with a minimal risk of missing VNT (<2%). It has to be acknowledged that similar classification rules (platelet count >100-120 3 10 9 cells/L and LSM <25 kPa) had been reported by different authors before the Baveno VI consensus conference (5) (6) (7) and in a recent abstract. (14) The new classification rule has been developed in the Anticipate cohort and validated in two additional cohorts from the United Kingdom and Spain, including in total over 900 patients with cACLD. The two validation cohorts presented a lower prevalence (4.5% and 7.7%, respectively) of VNT than the Anticipate cohort (13.8%). It could be argued that this would have favored the validation of the Expanded-Baveno VI criteria; however, the cACLD population that would mostly benefit from avoiding screening endoscopies is probably the patients with cACLD with LSM values between 10 kPa and 25 kPa. It is in the early cACLD population that the risk of having VNT is very low, and consequently, avoiding endoscopies is critical. Above LSM 25 kPa, the risk of having clinically significant portal hypertension is more than 90%-95% (12) and the presence of VNT rises rapidly. With the new Expanded-Baveno VI criteria, three additional patients with VNT were missed ( Table 4 ; Supporting Table S1 ). Two of these patients, both from the London cohort, presented one of the classification rule parameters very near the proposed thresholds (platelet count 115 3 10 9 cells/L and LSM 24.2 kPa). It seems evident that applying the new criteria to patients with values approaching the cutoffs may increase the risk of missing VNT. This is also evidenced, as discussed in the results, by the effect that the variability both in LSM (19) and platelet counts (20) might have in increasing this risk. Besides measuring liver stiffness with the best possible quality criteria, (21) it is advisable, in our opinion, to repeat the LSM and platelet count after a short period in patients with values close to the cutoffs to confirm that they remain in the low-risk group. One drawback of using a single cutoff to separate patients in two groups is there is always an unwanted loss of information. We might think that the risk of having VNT in all patients within the ExpandedBaveno VI criteria is 1.6%, while it is obvious that the real risk, better described in the 95% CI, ranges from 0% to at least 3%, being higher in patients approaching the cutoffs. For this reason, although we tend to work with binary decisions even though categorical decision rules are best suited for general recommendations, the information of the predicted risk by the continuous model of our prior Anticipate study (12) provides useful and complementary information for an individual patient. Both approaches point to the same conclusions and could be used in combination in real practice, especially in patients with values of platelets and an LSM closer to the thresholds of the Expanded-Baveno VI criteria.
Another important piece of information provided by the present study is that the new classification rule performs well when analyzed in the main etiologies of cACLD (Table 7) . HCV patients were clearly overrepresented in the cohort, and the Expanded-Baveno VI criteria performed very well in this population. However, it is reassuring that in our sample with around 100 patients each with cACLD due to alcoholic and nonalcoholic steatohepatitis, the performance of the new criteria was also very good. In patients with hepatitis B, although the number of patients is lower, only one VNT was missed. Finally, patients with cholestatic liver diseases constitute a special subgroup of patients who might have portal hypertension in early phases of the disease, and clearly our numbers are too low to draw conclusions.
The MELD 5 6 criteria seemed a promising tool when added to the Baveno VI criteria in the initial study. (13) Even more attractive was the proposal to use platelet count plus MELD 5 6, without the need of LSM. From the data of our three cohorts, it is clear that applying the MELD 5 6 criteria to patients beyond the Expanded-Baveno VI criteria can be safely done with an additional gain of spared endoscopies of around 5%. By contrast, we were unable to validate the classification rule of MELD 5 6 without LSM, which would lead to an unacceptable high rate of missed VNT.
Our study has limitations, many of which have been discussed. (8, 12) In short, the main limitations are the retrospective nature of the data, the time frames between endoscopy and LSM acquisition (up to 12 months), and the quality control of LSM and endoscopy reporting. Another important limitation is that including LSM in the classification criteria is, in itself, a limitation because transient elastography is not available in all centers. Moreover, we have to keep in mind that LSM cannot be performed in some patients (e.g., patients who are obese, although this can partially be solved with the use of an XL probe), and some factors, such as alcohol use, aminotransferases flares, or heart congestion, can increase liver stiffness and therefore provide falsely high LSM values. In these cases, an unneeded endoscopy might be performed. Finally, because the XL probe was not used in our study, information regarding its utility for the Expanded-Baveno VI criteria cannot be provided. Hence, in real-world practice, due to all the issues regarding LSM mentioned here, the Baveno VI criteria might not be applicable to all patients.
By contrast, the main strengths of our study are the large number of patients evaluated in many centers from different countries, the sequential validation process in external cohorts, and the similar performance of the new classification rule across different etiologies of cACLD.
In summary, the present study demonstrates that the Baveno VI criteria for avoiding screening endoscopy in patients with cACLD can be safely expanded. With the new Expanded-Baveno VI criteria (platelet count >110 3 10 9 cells/L 1 LSM <25 kPa), more endoscopies are spared (100% increase from 21% to 40%) with a minimal risk of missing VNT in most of the main etiologies of cACLD. The MELD 5 6 criteria can be safely added to the Expanded-Baveno VI criteria.
